ArticleCureus2026
A 76-Year-Old Man With Hemorrhagic Stroke, Recurrent Thromboembolic Events, and Atrial Fibrillation Under Optimal Medical Treatment: When Anticoagulants Fail.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current article demonstrates the clinical case of a 76-year-old man suffering from atrial fibrillation and encountering multiple thromboembolic events. Various novel anticoagulants in therapeutic doses were implemented and proved unsuccessful in preventing stroke, despite good compliance. Due to exclusion of alternative origins of thromboembolism and unfavorable interactions with the patient's medication, he was started on warfarin. He experienced a major intracranial hemorrhage, leading to cessation of antithrombotics for six weeks. Given the increased ischemic risk and scarcity of available options, he was scheduled for implantation of a Watchman left atrial appendage (LAA) occluder (Boston Scientific, Marlborough, MA, USA). Postprocedurally, the antithrombotic regimen comprised enoxaparin for six weeks, followed by dual antiplatelet therapy with aspirin and clopidogrel for six months once complete device endothelialization was confirmed, and finally lifelong aspirin monotherapy. To date, during a six-year follow-up period, the patient has not experienced hemorrhagic or thromboembolic events. Thus, our case report indicates that LAA occlusion could constitute a successful alternative method of stroke prevention in individuals with high ischemic risk despite optimal medical therapy or with contraindications to anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.